title: Clinical Features and Prognosis Analysis of Hodgkin Lymphoma: A Multicenter Retrospective Study Over a Decade of Patients in China.
abstract: There is little information available regarding Chinese patients with Hodgkin lymphoma (HL). We analyzed the clinical features, outcome, and prognostic factors of Chinese patients with HL, aiming to establish a new risk model for better risk-adapted therapeutic strategy.
  
  
  
  Patients with newly diagnosed HL at 4 medical centers from January 2000 to August 2014 were recruited.
  
  
  
  A total of 150 patients were reviewed. The median age was 30 years (range, 15-91 years). At completion of initial therapy, 73.65% of patients achieved complete remission. The 5-year event-free survival (EFS) of the entire cohort was 61.1%, the overall survival was 84.7%, and the disease-free survival was 78.8%. B symptoms, extranodal involvement, and International Prognostic Score ≥ 3 remained as independent prognostic factors of EFS. Patients who failed to reach complete remission on interim positron emission tomography/computed tomography or computed tomography had a significantly worse outcome than those who did. A new risk model incorporating traditional risk factors and interim response stratified patients into 3 classes, with a 5-year EFS of 100%, 83.1%, and 33.1%, respectively (P < .0001).
  
  
  
  General clinical features were comparable with those of Western patients, whereas therapeutic outcomes were slightly inferior. The novel risk assessment model showed potential as a more powerful prognostic tool by identifying 3 subsets of patients with significantly distinct outcomes, which warrants further validations.
authors.affiliation: Shanghai Institute of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
authors.forename: Wen-Yan
authors.initials: WY
authors.lastname: Yu
authors.affiliation: Department of Oncology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
authors.forename: Mei
authors.initials: M
authors.lastname: Geng
authors.affiliation: Department of Hematology, Shanghai North Station Hospital, Shanghai, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Hao
authors.affiliation: Department of Hematology, Shanghai Yang Pu Central Hospital Affiliated to Shanghai Tong Ji University, Shanghai, China.
authors.forename: Mei
authors.initials: M
authors.lastname: Chen
authors.affiliation: Department of Hematology, Rui Jin North Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
authors.forename: Su-Jiang
authors.initials: SJ
authors.lastname: Zhang
authors.affiliation: Shanghai Institute of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
authors.forename: Jin
authors.initials: J
authors.lastname: Wang
authors.affiliation: Shanghai Institute of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: jianqingmi@shsmu.edu.cn.
authors.forename: Jian-Qing
authors.initials: JQ
authors.lastname: Mi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002681:China; D018572:Disease-Free Survival; D005260:Female; D006689:Hodgkin Disease / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D011878:Radiotherapy; D012189:Retrospective Studies; D055815:Young Adult
keywords: Chemotherapy; Event-free survival; Prognostic factors; Risk model; Treatment outcome